Publications by authors named "Gerald Hanks"

Claim this Profile
P
Prostate-Specific Antigen After Neoadjuvant Androgen Suppression in Prostate Cancer Patients Receiving Short-Term Androgen Suppression and External Beam Radiation Therapy: Pooled Analysis of Four NRG Oncology Radiation Therapy Oncology Group Randomized Clinical Trials.
Christopher L Hallemeier, Peixin Zhang, Thomas M Pisansky, Gerald E Hanks, David G McGowan

Int J Radiat Oncol Biol Phys· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis.
Amar U Kishan, Xiaoyan Wang, Wendy Seiferheld, Laurence Collette, Kiri A Sandler, Gerald E Hanks

JAMA Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk factors for late bowel and bladder toxicities in NRG Oncology prostate cancer trials of high-risk patients: A meta-analysis of physician-rated toxicities.
Canhua Xiao, Jennifer Moughan, Benjamin Movsas, Andre A Konski, Gerald E Hanks

Adv Radiat Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duration of Androgen Deprivation in Locally Advanced Prostate Cancer: Long-Term Update of NRG Oncology RTOG 9202.
Colleen A F Lawton, Xiaolei Lin, Gerald E Hanks, Herbert Lepor, David J Grignon

Int J Radiat Oncol Biol Phys· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202.
Amin J Mirhadi, Qiang Zhang, Gerald E Hanks, Herbert Lepor, David J Grignon

Int J Radiat Oncol Biol Phys· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of biochemical failure classification on clinical outcome: a secondary analysis of Radiation Therapy Oncology Group 9202 and 9413.
Daniel A Hamstra, Kyounghwa Bae, Gerald Hanks, Chen Hu, William U Shipley

Cancer· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A tissue biomarker-based model that identifies patients with a high risk of distant metastasis and differential survival by length of androgen deprivation therapy in RTOG protocol 92-02.
Alan Pollack, James J Dignam, Dayssy A Diaz, Qian Wu, Radka Stoyanova, Gerald E Hanks

Clin Cancer Res· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer.
Niraj Pahlajani, Karen J Ruth, Mark K Buyyounouski, David Y T Chen, Eric M Horwitz, Gerald E Hanks

Int J Radiat Oncol Biol Phys· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: meta-analysis of radiation therapy oncology group trials.
Daniel A Hamstra, Kyounghwa Bae, Miljenko V Pilepich, Gerald E Hanks, David J Grignon

Int J Radiat Oncol Biol Phys· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of ultrahigh baseline PSA levels on biochemical and clinical outcomes in two Radiation Therapy Oncology Group prostate clinical trials.
George Rodrigues, Kyounghwa Bae, Mack Roach, Colleen Lawton, Bryan Donnelly, Gerald Hanks

Int J Radiat Oncol Biol Phys· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline serum testosterone in men treated with androgen deprivation therapy and radiotherapy for localized prostate cancer.
Mack Roach, Kyounghwa Bae, Colleen Lawton, B J Donnelly, David Grignon, Gerald E Hanks

Int J Radiat Oncol Biol Phys· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02.
Li-Yan Khor, Kyounghwa Bae, Rebecca Paulus, Tahseen Al-Saleem, M Elizabeth Hammond, Gerald E Hanks

J Clin Oncol· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial.
Michael E Ray, Kyounghwa Bae, Maha H A Hussain, Gerald E Hanks, William U Shipley

J Natl Cancer Inst· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.
Jason A Efstathiou, Kyounghwa Bae, William U Shipley, Gerald E Hanks, Miljenko V Pilepich

J Clin Oncol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
Jason A Efstathiou, Kyounghwa Bae, William U Shipley, Gerald E Hanks, Miljenko V Pilepich

Eur Urol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02.
Matthew R Smith, Kyounghwa Bae, Jason A Efstathiou, Gerald E Hanks, Miljenko V Pilepich

J Clin Oncol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.
Eric M Horwitz, Kyounghwa Bae, Gerald E Hanks, Arthur Porter, David J Grignon

J Clin Oncol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02.
Colleen A Lawton, Kyoungwha Bae, Miljenko Pilepich, Gerald Hanks, William Shipley

Int J Radiat Oncol Biol Phys· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31.
Jason A Efstathiou, Kyounghwa Bae, William U Shipley, Gerald E Hanks, Miljenko V Pilepich

Cancer· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202.
Mingxin Che, Michelle DeSilvio, Alan Pollack, David J Grignon, Varagur Mohan Venkatesan, Gerald E Hanks

Int J Radiat Oncol Biol Phys· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prostate cancer risk assessment program: a 10-year update of cancer detection.
Veda N Giri, Jennifer Beebe-Dimmer, Mark Buyyounouski, Andre Konski, Steven J Feigenberg, Gerald Hanks

J Urol· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial.
Li-Yan Khor, Kyounghwa Bae, Alan Pollack, M Elizabeth H Hammond, David J Grignon, Gerald E Hanks

Lancet Oncol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Racial differences in CYP3A4 genotype and survival among men treated on Radiation Therapy Oncology Group (RTOG) 9202: a phase III randomized trial.
Mack Roach, Michelle De Silvio, Timothy Rebbick, David Grignon, Marvin Rotman, Gerald Hanks

Int J Radiat Oncol Biol Phys· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202.
Arnab Chakravarti, Michelle DeSilvio, Min Zhang, David Grignon, Seth Rosenthal, Gerald Hanks

J Clin Oncol· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02.
Li Yan Khor, Jennifer Moughan, Tahseen Al-Saleem, Elizabeth H Hammond, Varagur Venkatesan, Gerald E Hanks

Clin Cancer Res· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis